A Phase 3 interventional study of Axicabtagene Ciloleucel and Platinum-containing Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Kite, A Gilead Company. Completed at 72 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Gilead Sciences.
Among the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 3, and was the 11th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 3
First in 1997; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 359 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 63 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
After completing the treatment period, all participants will be followed in the post-treatment follow-up period for up to 5 years. Thereafter, participants who received at least one dose of axicabtagene ciloleucel as protocol therapy will transition to a separate long term follow up (LTFU) study and complete the remainder of the 15-year follow-up assessments within KT-US-982-5968 (NCT05041309).
Key Inclusion Criteria:
proven large B-cell lymphoma (BCL) including the following types defined by World Health Organization (WHO) 2016.
disease after chemoimmunotherapy.
Refractory disease defined as no complete remission to first-line therapy; individuals who are intolerant to first-line therapy are excluded.
Individuals must have received adequate first-line therapy including at a minimum:
Adequate bone marrow function as evidenced by:
Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation antigen (CD) 19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. Participants who will achieve a partial response or complete response and subsequently experience disease progression may have an option to receive a second course of conditioning chemotherapy and axicabtagene ciloleucel.
Biological: Axicabtagene Ciloleucel · Drug: Cyclophosphamide · Drug: Fludarabine
Participants will receive 2 or 3, 21-day cycles of second-line chemotherapy: * R-ICE:rituximab 375mg/m\^2 before chemotherapy, ifosfamide 5g/m\^2 24 hours continuous infusion (CI) on Day 2+mesna, carboplatin area under the curve (AUC)5 Day 2, maximum dose 800mg, etoposide 100mg/m\^2/day on Days 1-3; * R-ESHAP:rituximab 375mg/m\^2 Day 1, etoposide 40mg/m\^2/day IV on Days 1-4, methylprednisolone 500mg/day IV on Days 1-4 or 5, cisplatin at 25mg/m\^2/day CI Days 1-4, cytarabine 2g/m\^2 on Day 5; * R-GDP:rituximab 375mg/m\^2 Day 1 (or Day 8), gemcitabine 1g/m\^2 on Days 1 and 8, dexamethasone 40mg on Days 1-4, cisplatin 75mg/m\^2 Day 1 or carboplatin area under the curve (AUC)=5; or * R-DHAP:rituximab 375mg/m\^2 before chemotherapy, dexamethasone 40mg/day on Days 1-4, high dose cytarabine 2g/m\^2 every 12 hours for 2 doses on Day 2 following platinum, cisplatin 100mg/m\^2 24 hours CI on Day 1 or oxaliplatin 100mg/m\^2. Responders will receive high-dose therapy and autologous stem cell transplant.
Drug: Platinum-containing Salvage Chemotherapy
Administered intravenously
Also known as: KTE-C19, axi-cel, Yescarta ®
Platinum-containing salvage chemotherapy (Rituximab-ifosfamide, carboplatin, etoposide (R-ICE), Rituximab-dexamethasone, cytarabine, cisplatin,oxaliplatin (R-DHAP), Rituximab-etoposide, methylprednisolone, cisplatin, cytarabine (R-ESHAP), or Rituximab-gemcitabine, dexamethasone, cisplatin/carboplatin (R-GDP) as selected by treating investigator).
Administered intravenously
Administered intravenously
Event Free Survival (EFS) Per Blinded Central Assessment
EFS:Time from randomization to disease progression (PD), best response of stable disease (SD) up to Day 150, start of new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD=Score 4 (uptake moderately \> liver) or 5 (uptake markedly \> liver and/or new lesions) with increased uptake from baseline; New fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology or in bone marrow; Individual node/lesion abnormal with longest diameter \> 1.5 cm, ≥ 50% increase from nadir; Splenic length increase \> 50% of prior increase beyond baseline or ≥ 2 cm increase if no prior splenomegaly; New/recurrent splenomegaly, progression of non-measurable lesions, new lesion, or new/recurrent bone marrow involvement. KM estimates was used for analysis.
Time frame: From randomization date up to a median follow-up: 24.9 months
Objective Response Rate (ORR) Per Blinded Central Assessment
ORR: Percentage of participants with CR (Complete Metabolic Response (CMR);Complete Radiologic Response (CRR)) or PR (partial metabolic response (PMR); partial radiologic response (PRR)).CMR: Positron emission tomography (PET) 5-point scale scores: 1-No uptake above background; 2-Uptake ≤mediastinum; 3-Uptake \>mediastinum but ≤liver, with/without residual mass; no new lesions, no FDG-avid disease in bone marrow. CRR: Target nodes/nodal masses regressed ≤1.5 cm in longest diameter, no extralymphatic sites, no non-measured lesions, normal organ size, no new sites, normal bone marrow morphology. PMR: Scores 4 (uptake moderately \>liver), 5 (uptake markedly \>liver, new lesions) with reduced uptake from baseline and residual mass, no new lesions. Responding at interim/residual disease at end of treatment. PRR: ≥50% decrease in sum of diameters of up to 6 target measurable lesions, no increase in non-measured lesions, spleen length decreased \>50% if previously enlarged, no new lesion sites.
Time frame: From randomization date up to a median follow-up: 24.9 months
Overall Survival (OS)
Overall survival is defined as the time from randomization to death from any cause. Kaplan-Meier (KM) estimates were used for analysis.
Time frame: Up to 74.9 months
Duration of Response (DOR) Per Blinded Central Assessments
DOR was defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and was the time from the first objective response per Lugano classification to disease progression or death from any cause. Objective response was defined in outcome measure 2 and disease progression was defined in outcome measure 1. KM estimates were used for analysis.
Time frame: From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (Up to 37.8 months)
Modified Event Free Survival (mEFS) Per Blinded Central Assessment
Modified event free survival is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.
Time frame: From randomization date up to a median follow-up: 24.9 months
EFS Per Investigator Disease Assessments
EFS was defined as the time from randomization to the earliest date of disease progression per the Lugano Classification, best response of stable disease (SD) up to and including Day 150, commencement of new lymphoma therapy, or death from any cause. Disease progression is defined in outcome measure 1.
Time frame: From randomization date up to a median follow-up: 47.2 months
Progression-Free Survival (PFS) Per Investigator Disease Assessments
PFS is defined as the time from the randomization date to the date of disease progression per Lugano classification or death from any cause. Disease progression is defined in outcome measure 1. KM estimates were used for analysis.
Time frame: From randomization date up to a median follow-up: 47.2 months
Modified Event Free Survival (mEFS) Per Investigator Assessment
mEFS is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.
Time frame: From randomization date up to a median follow-up: 47.2 months
Change From Baseline in Global Health Status Scores
Global health status was measured using European Organization for Research and Treatment of Cancer (EORTC) Quality Life Questionnaire (QLQ) C-30. This health related quality of life (HRQoL) questionnaire was comprised of 15 questions on functional scales, 13 questions on symptom scales and 2 on global health status scale. Global Health Status used a 7 point Likert-type scale of 1 (Very poor) to 7 (Excellent). All scores were transformed to 0-100. Higher scores for Global Health Status indicated better HRQoL.
Time frame: Baseline, Days 50, 100, and 150; Months 9, 12, 15, 18, 21 and 24
Change From Baseline in EORTC QLQ-C30 Physical Functioning Score
The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The Physical Functioning domain includes 5 questions in which participants were asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 7 (excellent). The 5 scores were transformed to a scale from 0 to 100, where a high score indicated better QoL. A positive change from baseline indicates better QoL.
Time frame: Baseline, Days 50, 100, 150, Months 9, 12, 15, 18, 21 and 24
Changes From Baseline in the European Quality of Life Five Dimensions Five Levels Scale Index Score
The Euro-QOL (EQ) Five Dimensions (5D) Five Levels (5L), EQ-5D-5L questionnaire was a generic measure of health status that provided a simple descriptive profile and a single index value. The EQ-5D-5L comprised 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health stated using a visual analog scale (VAS). The total score for EQ-5D-5L index was presented on a range from 0 to 1 where higher scores indicated better outcome. A positive change from Baseline indicates improvement.
Time frame: Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24
Change From Baseline in EQ-5D-5L VAS Scale Score
The EQ-5D-5L VAS is a 20-cm VAS for recording self-rated current HRQoL state and is used to describe the participants' health status on the day of the assessment. The EQ-5D-5L VAS score is recorded by each participant for his or her current HRQoL state and scored 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"). The value 100 indicates improvement.
Time frame: Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24
Number of Participants With Post-dose Anti-Axicabtagene Ciloleucel Antibodies
Time frame: Up to 74.9 months
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as any AE that begins on or after the first dose of study treatment (axicabtagene ciloleucel infusion or SOC), excluding bridging therapy.
Time frame: From first dose up to 61.8 months
Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher
Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.
Time frame: From first dose up to 61.8 months
Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher
Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.
Time frame: From first dose up to 61.8 months
Participants were enrolled at study sites in North America, Middle East, Europe, and Australia.
| Milestone | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Started | 180 | 179 |
| Completed | 2 | 67 |
| Not completed | 178 | 112 |
| Withdrew: Death | 84 | 91 |
| Withdrew: Rollover to long-term follow-up study criteria | 80 | 0 |
| Withdrew: Subject withdrawal of consent from further follow-up | 3 | 13 |
| Withdrew: Lost to follow-up | 9 | 5 |
| Withdrew: Reason not specified | 2 | 2 |
| Withdrew: Investigator decision | 0 | 1 |
EFS:Time from randomization to disease progression (PD), best response of stable disease (SD) up to Day 150, start of new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD=Score 4 (uptake moderately \> liver) or 5 (uptake markedly \> liver and/or new lesions) with increased uptake from baseline; New fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology or in bone marrow; Individual node/lesion abnormal with longest diameter \> 1.5 cm, ≥ 50% increase from nadir; Splenic length increase \> 50% of prior increase beyond baseline or ≥ 2 cm increase if no prior splenomegaly; New/recurrent splenomegaly, progression of non-measurable lesions, new lesion, or new/recurrent bone marrow involvement. KM estimates was used for analysis.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Event Free Survival (EFS) Per Blinded Central Assessment | 8.3 (4.5 to 15.8) | 2.0 (1.6 to 2.8) |
ORR: Percentage of participants with CR (Complete Metabolic Response (CMR);Complete Radiologic Response (CRR)) or PR (partial metabolic response (PMR); partial radiologic response (PRR)).CMR: Positron emission tomography (PET) 5-point scale scores: 1-No uptake above background; 2-Uptake ≤mediastinum; 3-Uptake \>mediastinum but ≤liver, with/without residual mass; no new lesions, no FDG-avid disease in bone marrow. CRR: Target nodes/nodal masses regressed ≤1.5 cm in longest diameter, no extralymphatic sites, no non-measured lesions, normal organ size, no new sites, normal bone marrow morphology. PMR: Scores 4 (uptake moderately \>liver), 5 (uptake markedly \>liver, new lesions) with reduced uptake from baseline and residual mass, no new lesions. Responding at interim/residual disease at end of treatment. PRR: ≥50% decrease in sum of diameters of up to 6 target measurable lesions, no increase in non-measured lesions, spleen length decreased \>50% if previously enlarged, no new lesion sites.
| percentage of participants | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Objective Response Rate (ORR) Per Blinded Central Assessment | 83 (77.1 to 88.5) | 50 (42.7 to 57.8) |
Overall survival is defined as the time from randomization to death from any cause. Kaplan-Meier (KM) estimates were used for analysis.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Overall Survival (OS) | NA (28.3 to NA) | 35.1 (18.5 to NA) |
DOR was defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and was the time from the first objective response per Lugano classification to disease progression or death from any cause. Objective response was defined in outcome measure 2 and disease progression was defined in outcome measure 1. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Duration of Response (DOR) Per Blinded Central Assessments | 26.9 (13.6 to NA) | 8.9 (5.7 to NA) |
Modified event free survival is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Modified Event Free Survival (mEFS) Per Blinded Central Assessment | 10.3 (5.0 to 21.5) | 2.0 (1.6 to 2.8) |
EFS was defined as the time from randomization to the earliest date of disease progression per the Lugano Classification, best response of stable disease (SD) up to and including Day 150, commencement of new lymphoma therapy, or death from any cause. Disease progression is defined in outcome measure 1.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| EFS Per Investigator Disease Assessments | 10.8 (5.0 to 25.5) | 2.3 (1.7 to 3.1) |
PFS is defined as the time from the randomization date to the date of disease progression per Lugano classification or death from any cause. Disease progression is defined in outcome measure 1. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Progression-Free Survival (PFS) Per Investigator Disease Assessments | 14.7 (5.4 to 43.5) | 3.7 (2.9 to 5.3) |
mEFS is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Modified Event Free Survival (mEFS) Per Investigator Assessment | 12.6 (5.0 to 29.1) | 2.3 (1.7 to 3.1) |
Global health status was measured using European Organization for Research and Treatment of Cancer (EORTC) Quality Life Questionnaire (QLQ) C-30. This health related quality of life (HRQoL) questionnaire was comprised of 15 questions on functional scales, 13 questions on symptom scales and 2 on global health status scale. Global Health Status used a 7 point Likert-type scale of 1 (Very poor) to 7 (Excellent). All scores were transformed to 0-100. Higher scores for Global Health Status indicated better HRQoL.
| Score on scale | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Score at Baseline | 68.6 ± 19.9 | 70.1 ± 23.1 |
| Change from Baseline at Study Day 50 | -7.4 ± 20.2 | -8.5 ± 22.7 |
| Change from Baseline at Study Day 100 | 1.3 ± 19.6 | -15.3 ± 22.7 |
| Change from Baseline at Study Day 150 | 5.9 ± 24.9 | -4.2 ± 23.7 |
| Change from Baseline at Study Month 9 | 8.0 ± 22.7 | 3.5 ± 23.7 |
| Change from Baseline at Study Month 12 | 8.6 ± 24.9 | 9.1 ± 20.2 |
| Change from Baseline at Study Month 15 | 9.0 ± 22.3 | 9.9 ± 18.9 |
| Change from Baseline at Study Month 18 | 10.2 ± 20.9 | 6.5 ± 21.3 |
| Change from Baseline at Study Month 21 | 10.0 ± 21.5 | 15.0 ± 19.6 |
| Change from Baseline at Study Month 24 | 8.6 ± 21.0 | 13.2 ± 17.2 |
The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The Physical Functioning domain includes 5 questions in which participants were asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 7 (excellent). The 5 scores were transformed to a scale from 0 to 100, where a high score indicated better QoL. A positive change from baseline indicates better QoL.
| Score on scale | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Score at Baseline | 83.5 ± 17.7 | 85.3 ± 18.9 |
| Change from Baseline at Study Day 50 | -12.9 ± 21.7 | -8.3 ± 17.5 |
| Change from Baseline at Study Day 100 | -1.8 ± 17.8 | -15.0 ± 19.1 |
| Change from Baseline at Study Day 150 | 1.3 ± 18.9 | -5.2 ± 21.3 |
| Change from Baseline at Study Month 9 | 4.1 ± 17.1 | -2.4 ± 23.5 |
| Change from Baseline at Study Month 12 | 3.4 ± 20.8 | 0.4 ± 20.3 |
| Change from Baseline at Study Month 15 | 3.9 ± 19.3 | 1.6 ± 16.1 |
| Change from Baseline at Study Month 18 | 5.0 ± 15.1 | 3.2 ± 17.9 |
| Change from Baseline at Study Month 21 | 6.0 ± 16.1 | 4.3 ± 21.4 |
| Change from Baseline at Study Month 24 | 3.7 ± 16.5 | 5.6 ± 8.0 |
The Euro-QOL (EQ) Five Dimensions (5D) Five Levels (5L), EQ-5D-5L questionnaire was a generic measure of health status that provided a simple descriptive profile and a single index value. The EQ-5D-5L comprised 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health stated using a visual analog scale (VAS). The total score for EQ-5D-5L index was presented on a range from 0 to 1 where higher scores indicated better outcome. A positive change from Baseline indicates improvement.
| Score on scale | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Score at Baseline | 0.803 ± 0.210 | 0.799 ± 0.250 |
| Change from Baseline at Study Day 50 | -0.049 ± 0.205 | -0.003 ± 0.198 |
| Change from Baseline at Study Day 100 | 0.012 ± 0.191 | -0.068 ± 0.246 |
| Change from Baseline at Study Day 150 | 0.050 ± 0.212 | 0.014 ± 0.208 |
| Change from Baseline at Study Month 9 | 0.064 ± 0.190 | 0.015 ± 0.197 |
| Change from Baseline at Study Month 12 | 0.072 ± 0.241 | 0.051 ± 0.200 |
| Change from Baseline at Study Month 15 | 0.051 ± 0.209 | 0.080 ± 0.125 |
| Change from Baseline at Study Month 18 | 0.094 ± 0.180 | 0.072 ± 0.188 |
| Change from Baseline at Study Month 21 | 0.089 ± 0.235 | 0.110 ± 0.177 |
| Change from Baseline at Study Month 24 | 0.051 ± 0.239 | 0.117 ± 0.138 |
The EQ-5D-5L VAS is a 20-cm VAS for recording self-rated current HRQoL state and is used to describe the participants' health status on the day of the assessment. The EQ-5D-5L VAS score is recorded by each participant for his or her current HRQoL state and scored 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"). The value 100 indicates improvement.
| Score on scale | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Score at Baseline | 72.4 ± 18.7 | 74.4 ± 20.1 |
| Change from Baseline at Study Day 50 | -1.9 ± 18.7 | -4.4 ± 16.7 |
| Change from Baseline at Study Day 100 | 4.0 ± 18.4 | -8.2 ± 19.8 |
| Change from Baseline at Study Day 150 | 9.1 ± 19.4 | -2.2 ± 22.2 |
| Change from Baseline at Study Month 9 | 11.4 ± 19.9 | 4.4 ± 19.0 |
| Change from Baseline at Study Month 12 | 10.1 ± 19.9 | 6.6 ± 17.8 |
| Change from Baseline at Study Month 15 | 10.7 ± 20.7 | 8.2 ± 13.7 |
| Change from Baseline at Study Month 18 | 15.1 ± 17.1 | 9.3 ± 13.6 |
| Change from Baseline at Study Month 21 | 14.0 ± 17.2 | 10.1 ± 14.3 |
| Change from Baseline at Study Month 24 | 10.9 ± 18.8 | 12.2 ± 15.3 |
| Participants | Axicabtagene Ciloleucel |
|---|---|
| Number of Participants With Post-dose Anti-Axicabtagene Ciloleucel Antibodies | 0 |
A TEAE was defined as any AE that begins on or after the first dose of study treatment (axicabtagene ciloleucel infusion or SOC), excluding bridging therapy.
| percentage of participants | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 100.0 | 100.0 |
Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.
| percentage of participants | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Hemoglobin (mmol/L) | 0 | 0 |
| Leukocytes (10^9/L) | 0 | 1 |
| Lymphocytes (10^9/L) | 0 | 0 |
| Alanine Aminotransferase (U/L) | 6 | 4 |
| Alkaline Phosphatase (U/L) | 1 | 1 |
| Aspartate Aminotransferase (U/L) | 6 | 2 |
| Bilirubin (umol/L) | 2 | 1 |
| Calcium (mmol/L) | 2 | 1 |
| Creatinine (umol/L) | 4 | 1 |
| Glucose (mmol/L) | 14 | 5 |
| Magnesium (mmol/L) | 2 | 0 |
| Potassium (mmol/L) | 0 | 1 |
| Sodium (mmol/L) | 0 | 0 |
Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.
| percentage of participants | Axicabtagene Ciloleucel | Standard of Care Therapy |
|---|---|---|
| Hemoglobin (mmol/L) | 41 | 44 |
| Leukocytes (10^9/L) | 95 | 56 |
| Lymphocytes (10^9/L) | 99 | 68 |
| Neutrophils (10^9/L) | 94 | 51 |
| Platelets (10^9/L) | 26 | 63 |
| Albumin (g/L) | 4 | 1 |
| Calcium (mmol/L) | 8 | 2 |
| Glucose (mmol/L) | 0 | 0 |
| Magnesium (mmol/L) | 2 | 3 |
| Phosphate (mmol/L) | 5 | 5 |
| Potassium (mmol/L) | 6 | 7 |
| Sodium (mmol/L) | 12 | 2 |
Collected over All-cause mortality and Adverse events: Up to 74.9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axicabtagene Ciloleucel Treatment | 81/180 (45%) | 96/170 (56.5%) | 170/170 (100%) |
| Standard of Care Therapy | 101/179 (56.4%) | 78/168 (46.4%) | 166/168 (98.8%) |
| Retreatment Axicabtagene Ciloleucel | 3/10 (30%) | 2/10 (20%) | 10/10 (100%) |
| Event | Axicabtagene Ciloleucel Treatment | Standard of Care Therapy | Retreatment Axicabtagene Ciloleucel |
|---|---|---|---|
| PyrexiaGeneral disorders | 27/170 | 8/168 | 0/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/170 | 22/168 | 0/10 |
| FuruncleInfections and infestations | 0/170 | 0/168 | 1/10 |
| Urinary tract infectionInfections and infestations | 3/170 | 0/168 | 1/10 |
| Neutrophil count decreasedInvestigations | 3/170 | 3/168 | 1/10 |
| EncephalopathyNervous system disorders | 17/170 | 1/168 | 0/10 |
| HypotensionVascular disorders | 15/170 | 3/168 | 1/10 |
| PneumoniaInfections and infestations | 16/170 | 4/168 | 0/10 |
| AphasiaNervous system disorders | 9/170 | 0/168 | 0/10 |
| Acute kidney injuryRenal and urinary disorders | 4/170 | 8/168 | 0/10 |
| Event | Axicabtagene Ciloleucel Treatment | Standard of Care Therapy | Retreatment Axicabtagene Ciloleucel |
|---|---|---|---|
| PyrexiaGeneral disorders | 149/170 | 40/168 | 9/10 |
| NauseaGastrointestinal disorders | 68/170 | 116/168 | 4/10 |
| HeadacheNervous system disorders | 69/170 | 43/168 | 6/10 |
| AnaemiaBlood and lymphatic system disorders | 71/170 | 90/168 | 4/10 |
| FatigueGeneral disorders | 69/170 | 87/168 | 2/10 |
| Neutrophil count decreasedInvestigations | 51/170 | 45/168 | 5/10 |
| NeutropeniaBlood and lymphatic system disorders | 75/170 | 28/168 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 71/170 | 66/168 | 2/10 |
| Sinus tachycardiaCardiac disorders | 58/170 | 16/168 | 4/10 |
| White blood cell count decreasedInvestigations | 46/170 | 37/168 | 4/10 |
The Full Analysis Set (FAS) consisted of all randomized participants.
| Age, Categorical(Participants) | Axicabtagene Ciloleucel | Standard of Care Therapy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 129 | 121 | 250 |
| >=65 years | 51 | 58 | 109 |
| Age, Continuous(years) | Axicabtagene Ciloleucel | Standard of Care Therapy | Total |
|---|---|---|---|
| Mean | 57.1 ± 12.0 | 57.4 ± 12.2 | 57.2 ± 12.1 |
| Sex: Female, Male(Participants) | Axicabtagene Ciloleucel | Standard of Care Therapy | Total |
|---|---|---|---|
| Female | 70 | 52 | 122 |
| Male | 110 | 127 | 237 |
| Ethnicity (NIH/OMB)(Participants) | Axicabtagene Ciloleucel | Standard of Care Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 8 | 18 |
| Not Hispanic or Latino | 167 | 169 | 336 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Axicabtagene Ciloleucel | Standard of Care Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 12 | 10 | 22 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Black or African American | 11 | 7 | 18 |
| White | 145 | 152 | 297 |
| More than one race | 10 | 8 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Axicabtagene Ciloleucel | Standard of Care Therapy | Total |
|---|---|---|---|
| United States | 130 | 120 | 250 |
| United Kingdom | 4 | 8 | 12 |
| Switzerland | 1 | 0 | 1 |
| Spain | 6 | 9 | 15 |
| Canada | 10 | 10 | 20 |
| Belgium | 4 | 3 | 7 |
| Netherlands | 11 | 14 | 25 |
| Sweden | 0 | 1 | 1 |
| Italy | 2 | 1 | 3 |
| Israel | 4 | 2 | 6 |
| Australia | 2 | 2 | 4 |
| France | 4 | 2 | 6 |
| Germany | 1 | 5 | 6 |
| Austria | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Jan 2018 to primary completion in Mar 2021, 37 months.
Results were first posted in Mar 2024, 2 years 11 months after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 37 months is below that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axicabtagene ciloleucel
Lymphoma, Large B-Cell, Diffuse →